{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:16:57Z","timestamp":1793117817616,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":255,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. In emergency hospital settings, rapid diagnosis and isolation of SARS\u2010CoV\u20102 patients are required. The aim of the study was to evaluate the performance of an antigen chemiluminescence enzymatic immunoassay (CLEIA) and compare it with that of Real\u2010time Reverse transcription\u2010Polymerase Chain Reaction (RT\u2010qPCR), the gold standard assay, to assess its suitability as a rapid diagnostic method for managing patients in the emergency department (ED). <jats:italic>Methods<\/jats:italic>. Consecutive patients with no previous history of SARS\u2010CoV\u20102 infection attending the ED of the Policlinico Hospital of Bari between 23rd October and 4th November 2020 were enrolled. Clinical and demographic data were collected for all patients. Nasopharyngeal swabs collected on admission were subjected both to molecular (RT\u2010qPCR) and antigen (CLEIA) tests for SARS\u2010CoV\u20102. The performance of the CLEIA antigen test was analyzed using R Studio software and Microsoft Excel. Receiver operating characteristics were also performed. <jats:italic>Results<\/jats:italic>. A total of 911 patients were enrolled, of whom 469 (51.5%) were male. Of the whole cohort, 23.7% tested positive for SARS\u2010CoV\u20102 by RT\u2010qPCR and 24.5% by CLEIA. The overall concordance rate was 96.8%. The sensitivity, specificity, positive predictive value, and negative predictive value of the antigen test were 94.9% (95% CI, 91.9\u201397.0), 97.4% (95% CI, 96.5\u201398.1), 91.9% (95% CI, 89.0\u201394.0), and 98.4% (95% CI, 97.4\u201399.1), respectively. The area under the curve (AUC) was 0.99. The kappa coefficient was 0.91. The overall positive and negative likelihood ratios were 37 (95% CI 23\u201058) and 0.05 (95% CI, 0.03\u20130.09), respectively. <jats:italic>Conclusions<\/jats:italic>. Data analysis demonstrated that the antigen test showed very good accuracy for discriminating SARS\u2010CoV\u20102\u2010infected patients from negative participants. The CLEIA is suitable for rapid clinical diagnosis of patients in hospital settings, particularly in EDs with a high prevalence of symptomatic patients and where a rapid turnaround time is critical. Timely and accurate testing for SARS\u2010CoV\u20102 plays a crucial role in limiting the spread of the virus.<\/jats:p>","DOI":"10.1155\/2021\/3893733","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T21:55:00Z","timestamp":1631570100000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Challenge of Using an Antigen Test as a Screening Tool for SARS\u2010CoV\u20102 Infection in an Emergency Department: Experience of a Tertiary Care Hospital in Southern Italy"],"prefix":"10.1155","volume":"2021","author":[{"given":"Daniela","family":"Loconsole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Centrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Morcavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Campanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sallustio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Casulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Accogli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-1256","authenticated-orcid":false,"given":"Maria","family":"Chironna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"e_1_2_8_1_2","unstructured":"World Health Organization (WHO) WHO Coronavirus Disease (COVID-19) Dashboard https:\/\/covid19.who.int\/."},{"key":"e_1_2_8_2_2","unstructured":"Ministero della Salute Norme circolari e ordinanze http:\/\/www.salute.gov.it\/portale\/nuovocoronavirus\/archivioNormativaNuovoCoronavirus.jsp?lingua=italiano&iPageNo=1."},{"key":"e_1_2_8_3_2","unstructured":"Governo Italiano Presidenza del Consiglio dei Ministri http:\/\/www.governo.it\/node\/14343."},{"key":"e_1_2_8_4_2","unstructured":"World Health Organization (WHO) COVID-19 strategy update 2020 https:\/\/www.who.int\/publications\/m\/item\/covid-19-strategy-update."},{"key":"e_1_2_8_5_2","unstructured":"World Health Organization (WHO) Laboratory testing for 2019 novel coronavirus - interim guidance 2020 https:\/\/apps.who.int\/iris\/handle\/10665\/330676."},{"key":"e_1_2_8_6_2","unstructured":"Istituto Superiore di Sanit\u00e0 (ISS) Nota tecnica ad interim - test di laboratorio per SARS-CoV-2 e loro uso in sanit\u00e0 pubblica 2020 https:\/\/www.iss.it\/."},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.11.025"},{"key":"e_1_2_8_8_2","unstructured":"Associazione Microbiologi Clinici Italiani (AMCLI) Indicazioni operative AMCLI su quesiti frequenti relativi alla diagnosi molecolare di infezione da SARS-CoV-2.2021 http:\/\/www.amcli.it\/wp-content\/uploads\/2021\/03\/01-2021_Indicazioni-operative-AMCLI_SARS-CoV-2.v4.pdf."},{"key":"e_1_2_8_9_2","unstructured":"Public Health Ontario An Overview of Cycle Threshold Values and Their Role in SARS-CoV-2 Real-Time PCR Test Interpretation 2020 https:\/\/www.publichealthontario.ca\/-\/media\/documents\/ncov\/main\/2020\/09\/cycle-threshold-values-sars-cov2-pcr.pdf?la=en."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.32.2001483"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1706"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0954"},{"key":"e_1_2_8_13_2","unstructured":"European Center for Disease Control and Prevention (ECDC) Options for the use of rapid antigen tests for COVID-19 in the EU\/EEA and the UK 2020 https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Options-use-of-rapid-antigen-tests-for-COVID-19.pdf."},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12121420"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104455"},{"key":"e_1_2_8_16_2","unstructured":"Centers for Disease Control and Prevention (CDC) Interim Guidance for Rapid Antigen Testing for SARS-CoV-2.2020 https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/antigen-tests-guidelines.html."},{"key":"e_1_2_8_17_2","unstructured":"NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3287615"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2012.031"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm695152a3"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.08.029"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0869-5"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7458.168"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.02.098"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.11.021"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2021.01.007"},{"key":"e_1_2_8_29_2","unstructured":"European Center for Disease Control and Prevention (ECDC) Risk related to spread of new SARSCoV-2 variants of concern in the EU\/EEA 2020 https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA.pdf."},{"key":"e_1_2_8_30_2","unstructured":"Istituto Superiore di Sanit\u00e0 (ISS) https:\/\/www.iss.it\/primo-piano\/-\/asset_publisher\/3f4alMwzN1Z7\/content\/id\/5624099."},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/MRA.01487-20"},{"key":"e_1_2_8_32_2","unstructured":"Istituto Superiore di Sanit\u00e0 (ISS) https:\/\/www.iss.it\/documents\/20126\/0\/Rapporto+indagine+varianti+SARS-CoV-2.pdf\/3ba8d61d-eeb2-4db2-c33f-250226fa73a7?t=1617119597042."},{"key":"e_1_2_8_33_2","unstructured":"World Health Organization (WHO) https:\/\/www.who.int\/csr\/don\/31-december-2020-sars-cov2-variants\/en\/."},{"key":"e_1_2_8_34_2","unstructured":"European Center for Disease Control and Prevention (ECDC) Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/clinical-considerations.html."}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2021\/3893733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2021\/3893733.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2021\/3893733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:19:09Z","timestamp":1735647549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2021\/3893733"}},"subtitle":[],"editor":[{"given":"San-Ji","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1155\/2021\/3893733"],"URL":"https:\/\/doi.org\/10.1155\/2021\/3893733","archive":["Portico"],"relation":{},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"value":"2314-6133","type":"print"},{"value":"2314-6141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"2021-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"3893733"}}